Discovery Programs

Galectin Therapeutics focuses on studying the science of galectin proteins and applying this knowledge in the clinic. Targeting galectin proteins in multiple diseases with galectin inhibitors will likely be important for many years in the drug development industry. To this end, we have established three important collaborations to discover new compounds that may be effective galectin inhibitors. This is an important goal as follow-on compounds for our drugs currently in development and to extend the potential indications and routes of administration.

Galectin Sciences was established through combining our efforts with SBH Sciences in Natick, MA. Galectin Sciences is seeking small molecule, non-carbohydrate molecules that can inhibit galectin molecules with the goal of developing oral therapies.

In addition, we established a collaborative drug discovery program with Dr. Geert-Jan Boons’ laboratory in the Complex Carbohydrate Research Center at the University of Georgia. The program is focused on the discovery of new carbohydrate molecules that can be used in the therapy of diseases where galectin proteins play a major role, including cancer, and inflammatory and fibrotic disorders.

Galectin Therapeutics has also worked closely with Kevin Mayo at the University of Minnesota examining the chemical interactions of belapectin (GR-MD-02) and other molecules with the Galectin receptor itself.

Scientific Collaboration

Galectin is interested in supporting innovative scientific research where galectins may play an important role. If you have an interesting idea, contact us to see if we may provide our galectin-3 inhibitor to support your preclinical studies.